Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-arm Phase II Study of Palbociclib Plus Endocrine Therapy in Patients With High Risk ER-positive/HER2-negative T1-2N0-1 Early Breast Cancer Incorporating GenesWell™ BCT

NCT04247633 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT04247633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04247633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-arm Phase II Study of Palbociclib Plus Endocrine Therapy in Patients With High Risk ER-positive/HER2-negative T1-2N0-1 Early Breast Cancer Incorporating GenesWell™ BCT
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
February 11, 2020
Completion date
February 28, 2025
Enrollment
578 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer